Interferon alpha treatment and endocrine disease

Journal of the Royal Society of Medicine

Volumn 96, Issue 10, 2003, Pages 481-485

  Chan, Wing Bun ^a   Chow, Chun Chung ^a   Cockram, Clive Stewart ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

ADRENAL DISEASE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL FEATURE; COMPARATIVE STUDY; DELTA AGENT HEPATITIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFECT; ENDOCRINE DISEASE; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS DISEASE; HYPOPITUITARISM; HYPOTHYROIDISM; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; PATIENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; THYROID FUNCTION; THYROID GLAND; THYROIDITIS; THYROTOXICOSIS;

EID: 0142010666     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.96.10.481     Document Type: Review

References (49)

1. Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Leukemia 2000;14:389-92
2. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002;36(5 Suppl 1):S114-20
3. Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992;3:35-41
4. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med 1993;119:312-23
5. Agarwala SS, Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Huntingt) 2002;16:1177-87; discussion 1190-2, 1197
6. Chedin P, Chanson P, Duranteau L, Guillausseau PJ, Lubetzki J. Dysthyroidism in patients treated with interferon alpha. Presse Med 1994;23:1659-63
7. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47
8. Murakami M, Kakizaki S, Takayama H, Takagi H, Mori M. Autoimmune thyroid disease induced by interferon therapy. Nippon Rinsho 1999;57:1779-83
9. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91
10. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interteron-alpha therapy. Clin Endocrinol (Oxf) 1996;44:635-42
11. Rocco A, Gargano S, Provenzano A, et al. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuroendocrinol Lett 2001;22:39-44
12. Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995;44:110-14
13. Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit 2001;7 (Suppl 1):221-5
14. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Médecine Interne et Maladies Infectieuses sur le Virus de l'Hépatite C. Medicine (Baltimore) 2000;79:47-56
15. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;158:1445-8
16. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999;50:503-9
17. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995;132:587-93
18. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997;20:374-80
19. Hsieh MC, Yu ML, Chuang WL, et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:431-7
20. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factors for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403
21. Murakami T, Masumoto T, Michitaka K, et al. Prediction of interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:528-31
22. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002;251:400-6
23. Amenomori M, Mori T, Fukuda Y, et al. Incidence and characteristics of thyroid dysfunction following interferon therapy in patients with chronic hepatitis C. Intern Med 1998;37:246-52
24. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002;25:624-30
25. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996;101:482-7
26. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-9
27. Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002;146:743-9
28. Papo T, Oksenhendler E, Izembart M, Leger A, Clauvel JP. Antithyroid hormone antibodies induced by interferon-alpha. J Clin Endocrinol Metab 1992;75:1484-6
29. Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988;24:1299-303
30. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83
31. Silvestri F, Virgolini L, Mazzolini A, et al. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 1994;79:367-70
32. Vallisa D, Cavanna L, Berte R, Merli F, Ghisoni F, Buscarini L. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995;93:31-5
33. Corssmit EP, Heyligenberg R, Endert E, Sauerwein HP, Romijn JA. Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab 1995;80:3140-4
34. Guerin V, Todd I, Hammond LJ, Bottazzo GF, Pujol-Borrell R, Feldmann M. Suppression of HLA class II expression on thyrocytes by interferon-alpha 1. Clin Exp Immunol 1990;79:341-5
35. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983;ii:1115-19
36. Yue SJ, Enomoto T, Matsumoto Y, Kawai K, Volpe R. Thyrocyte class I and class II upregulation is a secondary phenomenon and does not contribute to the pathogenesis of autoimmune thyroid disease. Thyroid 1998;8:755-63
37. Kawai K, Enomoto T, Fornasier V, Resetkova E, Volpe R. Differential effects of human interferon alpha and interferon gamma on xenografted human thyroid tissue in severe combined immunodeficient mice and nude mice. Proc Assoc Am Physicians 1997;109:126-35
38. Watson PF, Pickerill AP, Davies R, Weetman AP. Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 1994;79:355-60
39. Grubeck-Loebenstein B, Buchan G, Chantry D, et al. Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin Exp Immunol 1989;77:324-30
40. Durelli L, Ferrero B, Oggero A, et al. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 2001;57:1363-70
41. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992;340:548
42. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998;28:514-17
43. Betterle C, Fabris P, Zanchetta R, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000;23:1177-81
44. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83
45. Oshimoto K, Shimizu H, Sato N, Mori M. A case of Addison's disease which became worse during interferon therapy: [insulin secretion under hyposmolarity]. Nippon Naibunpi Gakkai Zasshi 1994;70:511-16
46. Knost JA, Sherwin S, Abrams P, Oldham RK. Increased steroid dependence after recombinant leucocyte interferon therapy. Lancet 1981;ii:1287-8
47. Gisslinger H, Svoboda T, Clodi M, et al. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993;57:489-95
48. Sakane N, Yoshida T, Yoshioka K, Umekawa T, Kondo M, Shimatsu A. Reversible hypopituitarism after interferon alfa therapy. Lancet 1995;345:1305
49. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002;32:163-73